AAA
FOLD

Affinity Asset Advisors’s Amicus Therapeutics FOLD Stock Holding History

Affinity Asset Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-111,400
Closed -$1.06M – 61
2021
Q3 		$1.06M Buy
+111,400
New +$1.14M 0.27% 55

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Affinity Asset Advisors's FOLD Position: Q4 2021 in Review

Affinity Asset Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 111,400 shares — an estimated $1.06M sold.

Affinity Asset Advisors first reported a position in FOLD in Q3 2021 and held it in 1 quarter. The position peaked at $1.06M in Q3 2021. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

  • Affinity Asset Advisors reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 111,400 Amicus Therapeutics shares in Q4 2021, an estimated $1.06M.
  • Affinity Asset Advisors first reported a position in Amicus Therapeutics in Q3 2021 and held it in 1 quarter.
  • Affinity Asset Advisors's Amicus Therapeutics position peaked at $1.06M in Q3 2021.
  • 223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Affinity Asset Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.